Wardwizard Healthcare Ltd Reports ₹0.32 Crore Q1 Net Loss

Wardwizard Healthcare Ltd reported a standalone net loss of ₹0.32 crore for the quarter ended June 30, 2026, compared with a ₹0.21 crore loss a year earlier. Sales increased 242.11% year-on-year to ₹0.65 crore, while the company’s operating margin remained negative at 50.76%.

What did Wardwizard Healthcare report for the June 2026 quarter?

Wardwizard Healthcare reported net sales of ₹0.65 crore and a net loss of ₹0.32 crore in the June 2026 quarter. The company had reported net sales of ₹0.19 crore and a net loss of ₹0.21 crore in the corresponding June 2025 quarter.

The increase in sales represents a 242.11% year-on-year rise from a low base. However, the higher revenue did not translate into a profit. The reported net loss widened by ₹0.11 crore from the loss recorded in the year-earlier quarter.

Operating performance also remained weak. Operating profit before depreciation, interest and tax, excluding other income, was a loss of ₹0.33 crore, compared with a loss of ₹0.47 crore in June 2025. The operating loss narrowed in absolute terms, but the operating margin was still negative.

The June quarter result followed a profitable March 2026 quarter, when Wardwizard Healthcare reported revenue of ₹0.57 crore and net profit of ₹0.34 crore. On a quarter-on-quarter basis, June revenue rose 14.0%, while the company moved back into a loss.

How do the June 2026 financial figures compare?

Wardwizard Healthcare’s June 2026 sales growth was substantial in percentage terms, but the company remained loss-making at the operating and net-profit levels. The comparison below uses ₹ crore, the unit used in the reported standalone results.

The June 2026 operating margin of negative 50.76% was better than the negative 215.79% reported a year earlier. This improvement reflects the increase in sales relative to the operating loss, though the business did not yet report a positive operating margin.

Interest expense was reported at nil for the June 2026 quarter, compared with ₹0.06 crore in June 2025. The reported loss before tax was ₹0.37 crore, compared with a ₹0.10 crore loss in the corresponding prior-year period.

Why did Wardwizard Healthcare’s quarterly result matter?

Wardwizard Healthcare’s result matters because it showed revenue growth alongside continued losses and a return to negative net profit after the March 2026 quarter. The June result indicates that higher sales alone were insufficient to cover the company’s operating costs during the period.

The company is classified as a micro-cap entity in the Trading and Distributors industry. For smaller listed businesses, changes in sales from a low base can produce large percentage movements. Investors may therefore assess both the absolute revenue figure of ₹0.65 crore and the company’s ability to improve margins.

Its annual-report disclosures for FY 2025-26 referred to capital restructuring and fundraising through warrants. The company also indicated that no dividend was planned because of losses. The stated use of funds included working capital and expansion-related requirements.

The annual report for FY 2025-26 was submitted on September 5, 2026. The filing covered corporate governance, financial statements and shareholder matters, while also outlining promoter investment and fund-utilisation plans cited by the company.

What was the status of the October 30 board meeting?

Wardwizard Healthcare informed BSE on October 26, 2026 that its board would meet on October 30, 2026 to consider and approve unaudited financial results for the quarter and half year ended September 30, 2026. The intimation was made under Regulations 29 and 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The board-meeting notice identified the proposed consideration of financial results but did not provide September-quarter revenue, profit, margin or earnings-per-share figures. Therefore, the June 2026 standalone figures remain the financial data available in the supplied disclosures for detailed comparison.

The company’s result-related disclosures are subject to SEBI’s listing rules, which require listed entities to follow prescribed processes for board approval and publication of financial results. The October 30 meeting was relevant because it covered both the second quarter and the first half of FY 2026-27.

For shareholders, the subsequent result filing is significant because it would provide the next reported measure of sales, profitability and the effect of the company’s capital and working-capital plans. No financial outcome from the October 30 meeting was specified in the board-meeting intimation.

How could the results affect investors and operations?

Wardwizard Healthcare’s June quarter showed that sales increased from the prior-year level, while the net loss widened to ₹0.32 crore. This combination makes margin improvement and cost management important measures for investors reviewing the company’s operating performance.

The shift from March 2026 net profit of ₹0.34 crore to a June 2026 net loss of ₹0.32 crore also highlights quarterly volatility. The March quarter had an operating margin of 62.52% and a net profit margin of 59.19%, compared with negative operating and net margins in June.

The company’s disclosures on warrants, promoter investments, working capital and expansion provide context for its financing plans. But the supplied information does not quantify the amount of funds to be raised, the timing of utilisation, or the operational outcome of those plans.

No dividend is planned in view of the losses referred to in the company’s annual-report disclosures. This means shareholders are focused on financial execution, capital-related actions and future reported results rather than near-term dividend distributions.

Conclusion

Wardwizard Healthcare reported a 242.11% rise in June 2026 sales to ₹0.65 crore, but remained loss-making with a net loss of ₹0.32 crore. The result marked an improvement in operating-loss margin from the year-earlier period, while also showing that the company had not converted revenue growth into net profitability.

The next item to watch is the outcome of the board meeting scheduled for October 30, 2026, which was set to consider unaudited results for the September 2026 quarter and first half. That disclosure is expected to provide the next set of reported figures on sales, margins and profitability, as well as context on the company’s stated working-capital and expansion plans.